|
|||||
|
|
Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib |
|
| Authors: | Lorraine Pelosof Steven Lemery Sandra Casak Xiaoping Jiang Lisa Rodriguez Vadryn Pierre Youwei Bi Jiang Liu Jeanne Fourie Zirkelbach Anuja Patel Kirsten B. Goldberg Amy E. McKee Patricia Keegan Richard Pazdur |
| Affiliation: | Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA |
| Abstract: | |
| Keywords: | Hepatocellular carcinoma Regorafenib Sorafenib |